High-Pressure Thermal Conversion of CBDA to CBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The medical use of marijuana has outpaced the clinical evaluation of specific cannabinoids, particularly Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA), which are stable in plants but need conversion to their active forms, Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC, for effective therapeutic use in conditions like epilepsy and Multiple Sclerosis.
Innovation Solution
High-pressure thermal conversion systems under controlled temperature and pressure using inert gases like carbon dioxide, nitrogen, and argon convert CBDA to CBD and Δ9-THCA to Δ9-THC, facilitating the production of pharmaceutical-grade cannabinoids for clinical evaluation and medical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If thermal conversion is performed under conventional conditions, then conversion of CBDA to CBD and Δ9-THCA to Δ9-THC occurs, but the process lacks control over temperature and pressure leading to inconsistent results
Solution Approach 1:
The patent applies parameter changes by systematically varying temperature and pressure conditions during thermal conversion. The system controls temperature ranges (e.g., 100-200°C) and pressure levels (e.g., 1-10 atm) to optimize conversion efficiency while maintaining consistency. This allows precise control over the decarboxylation process to achieve reliable and reproducible results.
Solution Approach 2:
The patent implements feedback mechanisms through controlled thermal conversion systems that monitor and adjust temperature and pressure parameters in real-time. This ensures consistent conversion conditions are maintained throughout the process, allowing for precise control over the transformation of CBDA to CBD and Δ9-THCA to Δ9-THC.
2Productivity
If high pressure thermal conversion is used to improve conversion efficiency, then pharmaceutical-grade cannabinoids are produced, but the process complexity and equipment requirements increase
Solution Approach 1:
The patent utilizes parameter changes by optimizing pressure and temperature conditions to enhance conversion efficiency. By controlling pressure within specific ranges (e.g., 1-10 atm) and temperature (e.g., 100-200°C), the system achieves efficient conversion of carboxylic cannabinoids while maintaining pharmaceutical-grade quality standards.
Solution Approach 2:
The patent employs an intermediary approach by using controlled thermal conversion systems that facilitate the decarboxylation process. The system acts as a mediator between the raw cannabinoid acids and the desired active forms, ensuring efficient and consistent transformation while managing equipment requirements through standardized processing conditions.
3Manufacturing precision
If conventional extraction methods are used, then cannabinoids are obtained, but the products lack standardization and pharmaceutical-grade purity
Solution Approach 1:
The patent applies parameter changes by establishing controlled conditions for thermal conversion and extraction. By specifying precise temperature ranges, pressure levels, and processing times, the system ensures consistent production of pharmaceutical-grade cannabinoids with standardized purity levels, facilitating regulatory compliance and quality control.
Solution Approach 2:
The patent implements feedback mechanisms through quality control systems that monitor product purity and consistency throughout the manufacturing process. This allows for real-time adjustments to ensure pharmaceutical-grade standards are met, ensuring standardized and reliable production of cannabinoids for medical applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method ensures efficient conversion of CBDA to CBD and Δ9-THCA to Δ9-THC, producing high-purity cannabinoids for therapeutic applications, addressing the need for standardized pharmaceutical-grade products for conditions like epilepsy and Multiple Sclerosis.
Implementation Method 1
These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water.
Implementation Method 2
The methods entail high pressure thermal conversion systems under controlled temperature and pressure.
Data Source
AI summary
This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.